Zepbound and Tirzepatide: Proven Effectiveness for Weight Loss

In the world of obesity treatment, a new class of drugs is redefining what is achievable. Leading this revolution is tirrizepatide, the active ingredient behind two headline-grabbing brand names: Mounjaro and, more recently, Zepbound. With weight loss results that rival bariatric surgery, this molecule represents a milestone in medicine.

But what exactly is tirzepatide? How does it work so effectively? And what is its status in Brazil? This detailed guide will unveil the science, studies, and approval behind what is considered the most potent pharmacological tool for weight loss to date.

What is Tirzepatide and How Does It Work? The Power of Double Agonism

Tirzepatide, developed by the pharmaceutical company Eli Lilly, is the first and only drug in a new class: a dual agonist of GIP and GLP-1 receptors. To understand what this means, we need to know about these two hormones.

GLP-1 (Glucagon-like peptide-1): This is a hormone naturally produced in our intestines after we eat. It has multiple beneficial effects, including:

Increased Satiety: Signals to the brain that we are satisfied, reducing hunger.

Delayed Gastric Emptying: Keeps food in the stomach for longer, prolonging the feeling of fullness.

Stimulates Insulin Release: Helps control blood sugar levels.

GIP (Glucose-dependent insulinotropic peptide): Like GLP-1, it is also an intestinal hormone that, in addition to helping regulate glucose, acts on brain receptors linked to appetite.

The great innovation of tirnezpatide is that it mimics the action of both hormones simultaneously. This synergistic action dramatically enhances the effects on satiety and metabolism. In simple terms, tirnezpatide acts directly on the appetite control centers in the brain, causing the patient to feel satisfied with less food and for much longer.

The Scientific Evidence: The Impressive SURMOUNT Studies

The effectiveness of tirnezitalide for weight loss is not speculation; it has been proven in a series of large-scale clinical studies known as the SURMOUNT program.

The most emblematic study, SURMOUNT-1, published in The New England Journal of Medicine, evaluated tirrizepatide in people with obesity or overweight, but without diabetes. The results were extraordinary:

After 72 weeks of treatment, participants who used the highest dose of tirnepide (15 mg) had an average weight loss of 22.5% from their initial body weight, which is equivalent to about 24 kg for a person weighing 106 kg.

To put this into perspective, this percentage of weight loss is something that, until now, was mostly achieved only with bariatric surgery. Other studies from the SURMOUNT program have confirmed these robust results and the maintenance of weight loss in the long term.

Zepbound vs. Mounjaro: What's the Difference?

This is a very common question. The answer is simple:

Mounjaro and Zepbound are exactly the same medication (tirzepatide), produced by the same company (Eli Lilly).

The only difference is the indication approved by the regulatory agencies:

Mounjaro: It was the first commercial name launched, with initial approval for the treatment of type 2 Diabetes Mellitus.

Zepbound: This is the newest brand name, specifically approved for the treatment of obesity and chronic overweight.

Approval in Brazil (ANVISA)

In Brazil, the approval process followed a similar path.

Mounjaro for Diabetes: ANVISA (Brazilian Health Regulatory Agency) approved Mounjaro in September 2023 for the treatment of type 2 diabetes.

Mounjaro for Obesity: In June 2025, ANVISA expanded the indication for Mounjaro in Brazil, approving its use also for the treatment of obesity and overweight.

Currently, the trade name Zepbound is not yet marketed in Brazil, but the drug Mounjaro has already been approved for this purpose.

Who can use it in Brazil?

According to the new package insert approved by ANVISA, Mounjaro may be indicated for:

People with a BMI (Body Mass Index) ≥ 30 kg/m² (obesity).

People with a BMI ≥ 27 kg/m² (overweight) who have at least one weight-related comorbidity, such as hypertension, dyslipidemia (high cholesterol), or sleep apnea.

Side Effects and Safety

Like all effective medications, tirnepide has side effects. The most common are gastrointestinal in nature, generally mild to moderate in intensity, and occur mainly at the beginning of treatment, during dose increases. These include:

Nausea

Diarrhea

Vomit

Constipation

It is crucial to emphasize that the use of tinzepide should always be prescribed and monitored by a specialist physician. Self-medication is extremely dangerous.

Conclusion:

Tirzepatide, whether under the names Zepbound or Mounjaro, represents an unprecedented advance in the pharmacological treatment of obesity. With efficacy proven by robust studies and now approved by ANVISA for this purpose in Brazil, it offers a powerful new hope for millions of people struggling with excess weight. However, its success and safety depend on a non-negotiable pillar: rigorous medical monitoring, which will ensure that the treatment is part of a complete and healthy approach to weight loss.